Brad Arthur, Black Rock Pharmacy co-owner, shares his take on the rising drug prices and the pharma supply chain.
Ross Muken, Evercore ISI managing director, discusses the pharmaceutical supply chain and profits.
Who gets how much of your healthcare dollar? CNBC's Meg Tirrell explains the drug pipeline.
Ralph Nader, former presidential candidate and consumer advocate, responds to Mylan and what she had to say about the EpiPen pricing outrage.
Earlier the iShares NASDAQ Biotechnology ETF (IBB) gained about 1 percent, but reversed its course after Clinton's tweet.
CNBC's Bob Pisani looks at the day's market action, including a look at which biotech stocks started to fall amid Mylan's EpiPen outrage.
Shares of Teva Pharmaceutical Industries are plunging, as U.S. patent offices invalidated their drug patent. CNBC's Meg Tirrell reports.
Paul Howard, Manhattan Institute Senior Fellow director of the Center for Medical Progress, and Robert Weissman, Public Citizen president, share their take on Mylan, the EpiPen pricing outrage and regulation versus the free market.
CNBC's Meg Tirrell reports the latest on Mylan and the EpiPen pricing outrage.
Margie Patel, Wells Fargo Funds, and Craig Hodges, Hodges Capital, discuss the current state of the markets, including their take on Mylan and the biotech sector. CNBC's Meg Tirrell also reports that senators are asking Mylan for more information on EpiPen pricing.
Hillary Clinton makes a statement on Mylan's EpiPen price hike. CNBC's Meg Tirrell reports.
Peter Pitts, former FDA associate commissioner and Center for Medicine in the Public Interest president, discusses FDA's role in the Mylan EpiPen outrage.
CNBC's Meg Tirrell reports the latest on Mylan and the EpiPen pricing outrage. Suzy Welch, LinkedIn contributing editor, weighs in.
Bill George, Harvard Business School professor & fmr. Medtronic chairman and CEO, shares his take on Mylan and the EpiPen pricing outrage.
CNBC's Meg Tirrell reports the latest on Mylan's controversial EpiPen price hike.
Shares of Clovis surge on positive FDA news, CNBC's Melissa Lee reports.
How is the EpiPen outrage impacting families, parents and children who need these products as protection against fatal allergy attacks? CNBC's Kate Kelly and Sue Herera discuss how its affecting their own children.
Tim Chiang, BTIG managing director, shares his take on Mylan, admid the EpiPen price outrage.
The "FMHR" traders; Sarat Sethi, Douglas C. Lane & Associates; and Stephanie Link, TIAA Global Asset Management, reveal their final trades, including CVS, Square and more.
Alex Tarrant, assistant editor at Dealreporter Europe, Mergermarket Group, shares his views on the deal between Pfizer and Medivation.